RIMSO-50 (Dimethyl Sulfoxide 500 mg/g) Product Monograph (2014)

Government Record · Mylan Pharmaceuticals ULC · March 11, 2014

Mylan Pharmaceuticals ULC, 2014-03-11: RIMSO-50 is a 50% dimethyl sulfoxide intravesical solution marketed in Canada by Mylan Pharmaceuticals ULC for interstitial cystitis. The DPD record lists it as Marketed, DIN 00493392, prescription schedule, route intravesical.

RIMSO-50 (dimethyl sulfoxide) is indicated for the symptomatic relief of patients with interstitial cystitis. RIMSO-50 has not been approved as being safe and effective for any other indication.

3

Mylan Pharmaceuticals ULC, 2014-03-11: RIMSO-50 is a 50% dimethyl sulfoxide intravesical solution marketed in Canada by Mylan Pharmaceuticals ULC for interstitial cystitis. The DPD record lists it as Marketed, DIN 00493392, prescription schedule, route intravesical. DPD current status Marketed (status date 2018-10-31); DIN 00493392; manufacturer Mylan Pharmaceuticals ULC; dosage form solution; route intravesical; Schedule PRESCRIPTION; ATC G04BX13. Product monograph dated 2014-03-11. Other Canadian DPD DMSO-active DINs are mostly cancelled or dormant: DOMOSO SOLN 90% (00259896, cancelled 1999-08-10), KEMSOL LIQUID 70% (00376167, cancelled 2011-07-22), DOMOSO GEL 90% (00462381, cancelled 1999-08-10), SYNOTIC OTIC SOLUTION (00507229, cancelled 1999-08-10), DOMOSO (02233028, cancelled 2013-07-17), DOMOSO (02233030, dormant 2018-07-20), SYNOTIC (02237340, cancelled 2018-07-20), DIMETHYL SULFOXIDE IRRIGATION USP (02243231, cancelled 2019-08-01). Study type: regulatory record.